Lamivudin var ikke genotoksisk in vivo ved doser, der medførte plasmakoncentrationer omkring 40- 50 gange højere end de forventede kliniske plasmakoncentrationer.
Lamivudine was not genotoxic in vivo at doses that gave plasma concentrations around 40-50 times higher than the anticipated clinical plasma levels.